Arda Therapeutics has filed a notice of an exempt offering of securities to raise $43,438,362.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Arda Therapeutics is raising up to $43,438,362.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Adam Freund played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Arda Therapeutics
Arda is a seed stage platform therapeutics company developing immunotherapies to remove pathological cells in chronic diseases and aging. We start by using single-cell data to identify pathogenic cells and specific markers to target them. We then design therapies to eliminate these – and only these – cells. We are initially focused on treating chronic diseases, with the long-term goal of extending healthy lifespan. In the last several years, a number of biotech startups have formed to remove senescent cells in a variety of indications. Cellular senescence is a cell state triggered by damage or stress and is characterized by growth arrest and a pro-inflammatory secretory phenotype. Senolytic companies arise from the thesis that removing senescent cells will lead to clinical benefit. Although there are conceptual overlaps between this approach and Arda’s, and we owe a debt to senolytic companies and academic labs for demonstrating key concepts, we believe senescent cells are just one example of a pathogenic cell state, with many more waiting to be discovered and targeted. Further, we believe that Arda’s strategy of using single cell patient data to drive target selection has higher odds of clinical translation than target selection based on the senescence disease hypothesis.
To learn more about Arda Therapeutics, visit http://www.ardatx.com/
Arda Therapeutics Linkedin Page: https://www.linkedin.com/company/arda-therapeutics/
Contact:
Adam Freund, Chief Executive Officer
650-804-8953
https://www.linkedin.com/in/adam-freund-0657654/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.